Stocksigma LogoStocksigma Logo

Q-Line Biotech Reports H1 FY27 Results with 10.0% EBITDA Growth

Q-Line Biotech reported a 5.8% YoY rise in H1 FY27 revenue to ₹152 Cr, while EBITDA increased 10.0% YoY to ₹40 Cr, expanding margins to 26.0%

Q-Line Biotech Reports H1 FY27 Results with 10.0% EBITDA Growth

Q-Line Biotech Ltd · Investor Presentation · 13 Nov 2026, 4:52 pm

Q-Line Biotech Reports H1 FY27 Results with 10.0% EBITDA Growth Q-Line Biotech reported a 5.8% YoY rise in H1 FY27 revenue to ₹152 Cr, while EBITDA increased 10.0% YoY to ₹40 Cr, expanding margins to 26.0%. PAT fell 8.1% YoY to ₹20 Cr, impacted by higher depreciation from the newly capitalized Unit 4 facility and base-year tax write-backs. Reagent sales rose 19.23%, whereas instrument revenue dropped 29.71% due to government supply execution delays. The company plans to operationalize Unit 4 fully in H2 FY27 and acquire a 70% stake in Heidelco Medicore.

Original exchange filing (PDF)

More announcements from Q-Line Biotech Ltd

All Q-Line Biotech Ltd announcements